Protective effects of a dual endothelin converting enzyme/neutral endopeptidase inhibitor on the development of pulmonary hypertension secondary to cardiac dysfunction in the rat

Pediatric Pulmonology

Volumn 45, Issue 11, 2010, Pages 1076-1085

  Dai, Zen Kong ^a   Hsieh, Chong Chao ^b   Chai, Chee Yin ^b   Wu, Jiunn Ren ^a   Jeng, Arco Y ^c   Chou, Shah Hwa ^b   Wu, Bin Nan ^d   Yeh, Jwu Lai ^d   Chen, Ing Jun ^d   Tan, Mian Shin ^b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

cGMP; endothelin converting enzyme inhibitor; eNOS; ET 1; NOx; pulmonary hypertension

Indexed keywords

CGS 26393; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; ENDOTHELIN CONVERTING ENZYME INHIBITOR; ENKEPHALINASE INHIBITOR; MESSENGER RNA; SMOOTH MUSCLE ACTIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AORTA; ARTERIAL WALL THICKNESS; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; HEART FAILURE; HEART PROTECTION; LUNG; LUNG ARTERY PRESSURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAT;

ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; BLOOD PRESSURE; ENDOTHELIN-1; HYPERTENSION, PULMONARY; LUNG; METALLOENDOPEPTIDASES; NEPRILYSIN; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHONIC ACIDS; PROTEASE INHIBITORS; PULMONARY ARTERY; RATS; RATS, WISTAR; TETRAZOLES; UP-REGULATION;

EID: 78449288013     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.21290     Document Type: Article

References (47)

1. Cody RJ, Haas GJ, Binkley PF, Caperes Q, Kelley R,. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992; 85: 504 - 509.
2. Yamaki S, Endo M, Takahashi T,. Different grades of medial hypertrophy and intimal changes in small pulmonary arteries among various types of congenital heart disease with pulmonary hypertension. Tohuku J Exp Med 1997; 182: 83 - 91.
3. Le Cras TD, Tyler RC, Xue C, Rengasamy A, Johns RA,. Chronic hypoxia upregulates endothelial and inducible nitric oxide synthase gene and protein expression in rat lung. Am J Physiol 1996; 270: L164 - L170.
4. Deruelle P, Grover TR, Abman SH,. Pulmonary vascular effects of nitric oxide-cGMP augmentation in a model of chronic pulmonary hypertension in fetal and neonatal sheep. Am J Physiol Lung Cell Mol Physiol 2005; 289: L798 - L806.
5. Oishi P, Sharma S, Grobe A, Azakie A, Harmon C, Johengen MJ, Hsu JH, Fratz S, Black SM, Fineman JR,. Alterations in cGMP, soluble guanylate cyclase, phosphodiesterase 5, and B-type natriuretic peptide induced by chronic increased pulmonary blood flow in lambs. Pediatr Pulmonol 2007; 42: 1057 - 1071.
6. Dai ZK, Tan MS, Chai CY, Yeh JL, Chou SH, Chiu CC, Jeng AY, Chen IJ, Wu JR,. Up-regulation of endothelial nitric oxide synthase and endothelin-1 in pulmonary hypertension secondary to heart failure in aorta-banded rats. Pediatr Pulmonol 2004; 37: 249 - 256.
7. Tan MS, Chai CY, Wu JR, Yeh JL, Chen IJ, Kwan AL, Jeng AY, Yang HY, Lee MH, Dai ZK,. Differential change in expression of pulmonary ET-1 and eNOS in rats after chronic left ventricular pressure overload. Exp Biol Med (Maywood) 2006; 231: 948 - 953.
8. Mason NA, Springall DR, Burke M, Pollock J, Mikhail G, Yacoub MH, Polak JM,. High expression of endothelial nitric oxide synthase in plexiform lesions of pulmonary hypertension. J Pathol 1998; 185: 313 - 318.
9. Tyler RC, Muramatsu M, Abman S, Stelzner TJ, Rodman DM, Bloch KD, Mcmurtry IF,. Variable expression of endothelial NO synthase in three forms of rat pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 1999; 276: L297 - L303. (Pubitemid 29102271)
10. Rhodes CJ, Davidson A, Gibbs JS, Wharton J, Wilkins MR,. Therapeutic targets in pulmonary arterial hypertension. Pharmacol Ther 2009; 121: 69 - 88.
11. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV,. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007; 131: 1917 - 1928.
12. Ertl G, Bauersachs J,. Endothelin receptor antagonists in heart failure: current status and future directions. Drugs 2004; 64: 1029 - 1040.
13. Nguyen QT, Cernacek P, Calderoni A, Stewart DJ, Picard P, Sirois P, White M, Rouleau JL,. Endothelin A receptor blockade causes adverse left ventricular remodeling but improves pulmonary artery pressure after infarction in the rat. Circulation 1998; 98: 2323 - 2330.
14. Turner AJ, Isaac RE, Coates D,. The neprilysin (NEP) family of zinc metalloendopeptidases: genomics and function. Bioessays 2001; 23: 261 - 269.
15. Isaka D, Emoto N, Raharjo SB, Yokoyama M, Matsuo M,. The effects of phosphoramidon on the expression of human endothelin-converting enzyme-1 (ECE-1) isoforms. J Cardiovasc Pharmacol 2003; 42: 136 - 141.
16. Trapani AJ, Lombaert SD, Kuzmich S, Jeng AY,. Inhibition of big ET-1-induced pressor response by an orally active dual inhibitor of endothelin-converting enzyme and neutral endopeptidase 24.11. J Cardiovasc Pharmacol 1995; 26: S69 - S71.
17. Jeng AY,. Therapeutic potential of endothelin-converting enzyme inhibitors. Exp Opin Ther Patents 1997; 7: 1283 - 1295.
18. Mulder P, Barbier S, Monteil C, Jeng AY, Henry JP, Renet S, Thuillez C,. Sustained improvement of cardiac function and prevention of cardiac remodeling after long-term dual ECE-NEP inhibition in rats with congestive heart failure. J Cardiovasc Pharmacol 2004; 43: 489 - 494.
19. Mellin V, Jeng AY, Monteil C, Renet S, Henry JP, Thuillez C, Mulder P,. Triple ACE-ECE-NEP inhibition in heart failure: a comparison with ACE and dual ECE-NEP inhibition. Cardiovasc Pharmacol 2005; 46: 390 - 397.
20. Emoto N, Raharjo SB, Isaka D, Masuda S, Adiarto S, Jeng AY, Yokoyama M,. Dual ECE/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats. Hypertension 2005; 45: 1145 - 1152.
21. Wright JL, Jeng AY, Battistini B,. Effect of ECE and NEP inhibition on cigarette smoke-induced cell proliferation in the rat lung. Inhal Toxicol 2001; 13: 497 - 511.
22. Navarrete CT, Devia C, Lessa AC, Hehre D, Young K, Martinez O, Bancalari E, Suguihara C,. The role of endothelin converting enzyme inhibition during group B streptococcus-induced pulmonary hypertension in newborn piglets. Pediatr Res 2003; 54: 387 - 392.
23. Tamanoto T, Wada A, Tsutamoto T, Ohnishi M, Horie M,. Long-term treatment with a phoshpodiesterase type 5 inhibitor improve pulmonary hypertension secondary to heart failure through enhancing the natriuretic peptides-cGMP. J Cardiovasc Pharmacol 2004; 44: 596 - 600.
24. Campbell DJ,. Vasopeptidase inhibition: a double-edged sword? Hypertension 2003; 41: 383 - 389.
25. Cargill RI, Lipworth BJ,. Acute effects of ANP and BNP on hypoxic pulmonary vasoconstriction in humans. Br J Clin Pharmacol 1995; 40: 585 - 590.
26. Lammersa AE, Hislopb AA, Hawortha SG,. Prognostic value of B-type natriuretic peptide in children with pulmonary hypertension. Int J Cardiol 2009; 135: 21 - 26.
27. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002; 287: 1531 - 1540.
28. Storme L, Parker TA, Kinsella JP, Rairigh RL, Abman SH,. Chronic hypertension impairs flow-induced vasodilatation and augments the myogenic response in fetal lung. Am J Physiol Lung Cell Mol Physiol 2002; 282: L56 - L66.
29. Jasmin JF, Lucas M, Cernacek P, Dupuis J,. Effectiveness of a nonselective ETA/B and a selective ETA antagonist in rats with monocrotaline-induced pulmonary hypertension. Circulation 2001; 103: 314 - 318.
30. Abman SH,. Role of endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Annu Rev Med 2009; 60: 13 - 23.
31. Wada A, Tsutamoto T, Ohnishi M, Sawaki M, Fukai D, Maeda Y, Kinoshita M,. Effects of a specific endothelin-converting enzyme inhibitor on cardiac, renal, and neurohumoral functions in congestive heart failure: comparison of effects with those of endothelin A receptor antagonism. Circulation 1999; 99: 570 - 577.
32. Chang CZ, Winardi D, Lin CL, Kwan AL, Jeng AY, Kassell NF, Howng SL, Lee KS,. Attenuation of hemolysate-induced cerebrovascular endothelial cell injury and of production of endothelin-1 and big endothelin-1 by an endothelin-converting enzyme inhibitor. Surg Neurol 2002; 58: 181 - 187.
33. Wypij DM, Nichols JS, Novak PJ, Stacy DL, Berman J, Wiseman JS,. Role of maschymase T cell in the extracellular processing of big-endothelin-1 to endothelin. Biochem Pharmacol 1992; 43: 845 - 853.
34. Simonova AI, Pozdneev VF, Gomazkov OA, Medvedeva NA,. Chronic treatment with an endothelin-converting enzyme inhibitor reduces the development of hypoxia-induced pulmonary hypertension in rat. Ross Fiziol Zh Im I M Sechenova 2008; 94: 777 - 784.
35. Wedgwood S, McMullan DM, Bekker JM, Fineman JR, Black SM,. Role for endothelin-1-induced superoxide and peroxynitrite production in rebound pulmonary hypertension associated with inhaled nitric oxide therapy. Circ Res 2001; 89: 357 - 364.
36. Pussard G, Gascard JP, Gorenne I, Labat C, Norel X, Dulmet E, Brink C,. Endothelin-1 modulates cyclic GMP production and relaxation in human pulmonary vessels. J Pharmacol Exp Ther 1995; 274: 969 - 975.
37. Thorin E, Lucas M, Cernacek P, Dupuis J,. Role of ET (A) receptors in the regulation of vascular reactivity in rats with congestive heart failure. Am J Physiol Heart Circ Physiol 2000; 279: H844 - H851.
38. de Andrade CR, Leite PF, Montezano AC, Casolari DA, Yogi A, Tostes RC, Haddad R, Eberlin MN, Laurindo FR, de Souza HP, Correa FM, de Oliveira AM,. Increased endothelin-1 reactivity and endothelial dysfunction in carotid arteries from rats with hyperhomocysteinemia. Br J Pharmacol 2009; 157: 568 - 580.
39. Homma N, Nagaoka T, Morio Y, Ota H, Gebb SA, Karoor V, McMurtry IF, Oka M,. Endothelin-1 and serotonin are involved in activation of Rho A/Rho kinase signaling in the chronically hypoxic hypertensive rat pulmonary circulation. J Cardiovasc Pharmacol 2007; 50: 697 - 702.
40. Takemoto M, Sun J, Hiroki J, Shimokawa H, Liao JK,. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 2002; 106: 57 - 62.
41. Gien J, Seedorf GJ, Balasubramaniam V, Tseng N, Markham N, Abman SH,. Chronic intrauterine pulmonary hypertension increases endothelial cell Rho kinase activity and impairs angiogenesis in vitro. Am J Physiol Lung Cell Mol Physiol 2008; 295: L680 - L687.
42. Kim J, Cho Y, Kim B, Kim Y, Lee G,. Role of Rho GTPase in the endothelin-1-induced nuclear signaling. Biochem Biophys Res Commun 1997; 232: 223 - 226.
43. A receptor-mediated generation of hydrogen peroxide. Am J Physiol Lung Cell Mol Physiol 2005; 288: L480 - L487.
44. Rex S, Schaelte G, Metzelder S, Flier S, de Waal EE, Autschbach R, Rossaint R, Buhre W,. Inhaled iloprost to control pulmonary artery hypertension in patients undergoing mitral valve surgery: a prospective, randomized- controlled trial. Acta Anaesthesiol Scand 2008; 52: 65 - 72.
45. Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, Tawakol A, Gerszten RE, Systrom DM, Bloch KD, Semigran MJ,. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007; 116: 1555 - 1562.
46. Kaluski E, Cotter G, Leitman M, Milo-Cotter O, Krakover R, Kobrin I, Moriconi T, Rainisio M, Caspi A, Reizin L, Zimlichman R, Vered Z,. Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension-a multi-center randomized study. Cardiology 2008; 109: 273 - 280.
47. Robins SP, Børnerheim R, Asberg A, Attramadal H,. Early intervention with a potent endothelin-A/endothelin-B receptor antagonist aggravates left ventricular remodeling after myocardial infarction in rats. Basic Res Cardiol 2002; 97: 239 - 247.